Company Active LTD

Company profile

Blueberry Therapeutics Limited

Blueberry Therapeutics Modern Drug Discovery & Development

Blueberry Therapeutics is a drug discovery and development company developing innovative nanomedicines in dermatology

CRN
07839535
Founded
2011
Age
14

Overview

Legal name
BLUEBERRY THERAPEUTICS LIMITED
Region
Unknown
Registered address
KROLL ADVISORY LTD, THE CHANCERY
58 SPRING GARDENS
MANCHESTER
GREATER MANCHESTER
M2 1EW
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
23 Jun
2026

Liquidation Voluntary Creditors Return Of Final Meeting

Insolvency

LIQ14 | Transaction MzUyNjAwNzg4MGFkaXF6a2N4 | Paper/PDF filed

Published 23 Jun 2026 23:03

28 Feb
2025

Accounts due

Accounts Due

Next accounts due date

06 Jan
2025

Confirmation statement due

Confirmation Due

Next confirmation statement due date

23 Dec
2023

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 May
2023

Accounts filed

Accounts

Last accounts made up date

08 Nov
2011

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2013
Funded years
2013, 2015, 2017, 2020
Age at first award
1 years

Projects

2020 Collaborative R&D Lead participant

Development of a coupled inactivating transport medium and RNA purification protocol for SARS-CoV-2

1 Aug 2020 to 30 Sep 2021

Awarded
£66,132
Total cost £66,132

The standard method for detecting SARS-CoV-2, the virus responsible for causing COVID-19, is called "RT-PCR" (reverse transcription, polymerase chain reaction). RT-PCR works by directly detecting the virus genetic material in patient samples and as such it requires the virus genetic material (its genome) to be intact in these samples in order to work. Bec...

2017 Feasibility Studies Lead participant

Assessment of novel nanoformulations for the treatment of acne

1 Jul 2017 to 31 Mar 2018

Awarded
£88,981
Total cost £127,115

Acne is a common disease, which can turn into a serious chronic disorder leading to permanent scaring and disfigurement. The current market for acne treatments is worth approximately $2.8 billion/annum (2016) but is dominated by poorly efficacious over-the-counter treatments, which are often reformulations of the same active ingredients (e.g. benzoyl pero...

2015 GRD Proof of Market Lead participant

Nanoparticle Formulation for the Treatment of Tinea Pedis

1 Jun 2015 to 30 Nov 2015

Awarded
£24,419
Total cost £40,699

Tinea pedis, also known as athlete’s foot, is a common dermatophytic infection, which is extremely difficult to eradicate. Its symptoms include pruritic, scaly soles and often painful fissures between the toes. Tinea pedis is currently treated with topical or oral antifungals, which are usually used for 1-6 weeks. However recurrences are common with up to...

2013 Feasibility Studies Lead participant

Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection

1 Aug 2013 to 31 Jul 2014

Awarded
£150,000
Total cost £212,717

The spread of multi-drug resistance (MDR) threatens to change the face of health care worldwide, crippling hospital units that rely on the ability to control infections in patients with weakened immune systems. We risk returning to a "pre-antibiotic" era unless we can develop new approaches to tackling bacterial resistance. Blueberry Therapeutics aims to ...

Product types

Collaborative R&D Feasibility Studies GRD Proof of Market